ev3 Inc

ev3 — Q2 2009 Earnings Presentation

19 slides from ev3's earnings presentation, Jul 28, 2009

  1. Slide 1: Q2 '09 Highlights

    Q2 '09 Highlights July 28, 2009

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Statements contained in this presentation that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements often can be identified by words such as "expect," "anticipate," "intend,

  3. Slide 3: Use of Non-GAAP Financial Measures

    Use of Non-GAAP Financial Measures ev3 uses certain non-GAAP financial measures in this presentation. ev3 uses non- GAAP financial measures as supplemental measures of performance and believes these measures provide useful information to investors in evaluating our operations, period over period. Ho

  4. Slide 4: Q2 '09 Financial Summary

    Q2 '09 Financial Summary Net product sales of $109.1 million +7% vs. Q2 2008; +12% constant currency* Peripheral vascular sales, excluding atherectomy*, +9% vs. Q2 2008; +13% constant currency* Peripheral stents +9% vs. Q2 2008; +14% constant currency* Atherectomy +21% vs. Q1 2009 Neurovascular sale

  5. Slide 5: Actual Results vs. Last Quarter & Year Ago

    Actual Results vs. Last Quarter & Year Ago *Constant Currency; For reconciliations, see our website at www.ev3.net. **All quarters presented are adjusted for amortization and non-cash stock-based compensation. Q2 2009 is also adjusted for accounting charges relating to the change in fair value of co

  6. Slide 6: Total Q2 '09 Product Revenue Growth of 12%*

    Total Q2 '09 Product Revenue Growth of 12%* Q3 Q4 Q1 Q2 Q2 East 100 105.6 100.4 101.5 109.1 Total Worldwide Product Sales ($M) Q3 Q4 Q1 Q2 Q2 East 36.6 39.4 38.7 35.9 41.4 Total International ($M) +28%* Q3 Q4 Q1 Q2 Q2 East 66.9 68.1 66.2 70.8 72 Worldwide Peripheral Vascular ($M) +5%* Q3 Q4 Q1 Q2 Q2

  7. Slide 7: Balance Sheet is Strengthening - We are Generating Cash

    Q2 08 Q3 08 Q4 08 Q1 09 Q2 09 East 38.7 45.9 59.7 66.9 60.4 Balance Sheet is Strengthening - We are Generating Cash Cash / Cash Equivalents Cash flow from operating activities totaled $20.0M in Q2 '09 Cash/cash equivalents decreased $6.6M Q2 '09 vs Q1 '09 due to Chestnut acquisition Inventory days d

  8. Slide 8: Improving Cost Structure - Continuing Progress

    Improving Cost Structure - Continuing Progress Q2 08 Q2 09 East 0.664 0.721 Gross Margin % of sales SG&A % of sales Q2 08 Q2 09 East 0.61 0.5 Favorable product mix, improved yields & labor efficiency, increased volumes Continued focus on leveraging cost structure and improving margins 8

  9. Slide 9: Increasing Peripheral Vascular Sales Force Productivity in U.S.

    Annualized Net Sales Per Territory Q2'09 up 20% vs. Q4'08 Key Drivers Atherectomy Clinical Specialists Corporate Account penetration Referral Market development DEFINITIVE clinical data Neuro business already > $2M per territory 9 Q4'08 Q1'09 Q2'09 Goal East 1.5 1.6 1.8 2 Increasing Peripheral Vascu

  10. Slide 10: Financial Summary: Continuing to Improve Performance

    Financial Summary: Continuing to Improve Performance Net Product Sales* $101,509 $100,018 $105,656 $100,395 $109,086 Gross Profit $71,528 $68,747 $71,316 $69,407 $78,608 Gross Margin 66.4% 64.2% 67.2% 69.1% 72.1% Net Income (loss) $(27,422) $(7,310) $(291,120) $(1,809) $23,989 Adjusted net EPS (loss

  11. Slide 11: Guidance - As of July 28, 2009

    Guidance - As of July 28, 2009 Full-Year 2009 Guidance Raised Revenues: Q3 2009: $109 to $112 million Full-Year 2009: $435 to $445 million Adjusted EPS1 per diluted share: Q3 2009: $0.09 to $0.121,2 Full-Year 2009: $0.47 to $0.531,2 Adjusted EPS guidance is based on weighted average diluted shares o

  12. Slide 12: Business Model Structure - Select P&L Information

    2008 % of sales 2007 2009 Goal Business Model Structure - Select P&L Information Sales 100% 100% 100% Gross margin 66% 65% 71% Selling, general & administrative* 55% 69% 51% Taxes** 0.4% 0.3% 1% Research & development 12% 17% 11% Stock-based comp, amortization & contingent consideration 11% 11% 10%

  13. Slide 13: Continue to Stay Focused on Profitable Growth

    Continue to Stay Focused on Profitable Growth Long-term profitable revenue growth Improve cost structure Increase sales force productivity Grow international sales Clinical evidence New products 1 2 3 4 5

  14. Slide 14: Recent Acquisition: Chestnut Medical Technologies, Inc.

    Recent Acquisition: Chestnut Medical Technologies, Inc. Founded to pioneer new minimally invasive therapies for interventional neuroradiology Develops technologies that are easier to use improve outcomes reduce complications in the treatment of neurovascular disease Chestnut's first products: Alliga

  15. Slide 15: Acquisition Summary: Chestnut Medical Technologies, Inc.

    Acquisition Summary: Chestnut Medical Technologies, Inc. Acquisition closed on June 23, 2009 $79.4 million upfront payment $26.2M in cash (33% of total) $53.2M in stock (67% of total) 5.06 million shares at $10.51 per share Value difference in upfront payment relates to 10 day average stock price of

  16. Slide 16: Pipeline Embolization Device (PED): The Future of Aneurysm Treatment

    Pipeline Embolization Device (PED): The Future of Aneurysm Treatment Implant Performance 3 to 5-fold increase in implant surface coverage compared to intracranial stents1 85% reduction in circulation within aneurysm2 Secure delivery system for accurate PED placement Deliverability Flexibility combin

  17. Slide 17: In Summary: Chestnut Medical is an Excellent Fit

    In Summary: Chestnut Medical is an Excellent Fit Complementary growth platform that fits our mission - broadens product portfolio for aneurysm treatment and offers first-mover advantage in flow diversion devices Compelling initial published clinical data compared to existing treatment alternatives P

  18. Slide 18: Why Invest in ev3

    Why Invest in ev3 I N S U M M A R Y 18 Peripheral vascular & Neurovascular procedures less vulnerable to macro-economic environment broadest product offering in $2B growing global market Generating cash & clear roadmap for sustained, profitable growth improved productivity, clinical evidence, new pr

  19. Slide 19: Q2 '09 Highlights

    Q2 '09 Highlights July 28, 2009

ev3 — Q2 2009 Earnings Presentation on 6ix